TOP 100 MAGAZINE

Serguei Melnik
​​

 

At a moment when medicine is being forced to reconcile compassion with caution, Serguei Melnik is helping redefine what responsible innovation looks like. As president, co-founder, and chairman of Nutribrand, Serguei is leading the development of a technology that does not blunt the effectiveness of life-saving pain management, but fundamentally changes how safely it can be delivered. His work centers on AVERSA™, a breakthrough abuse-deterrent transdermal platform designed to confront one of healthcare’s most difficult paradoxes: Fentanyl.

 

While Fentanyl is among the most effective painkillers available, its misuse has made clinicians increasingly hesitant to prescribe it, even to patients with debilitating chronic pain.

 

Background Built for Complex Problems

 

Serguei’s path to pharmaceutical innovation is rooted in decades of high-level business, legal, and operational leadership. He has advised companies navigating U.S. financial markets, helped foreign organizations establish compliant legal and financial frameworks in the United States, and guided complex restructurings at the executive and board levels. That experience sharpened his ability to manage risk, regulation, and scale—skills that now translate directly into building a company prepared to operate in one of the most scrutinized sectors in healthcare.

 

The AVERSA™ Technology Difference

 

Nutribrand’s flagship innovation, AVERSA™, is a first-of-its-kind abuse-deterrent transdermal technology, with its initial application focused on a fentanyl patch. Unlike existing pain patches, AVERSA™ does not alter the drug matrix or interfere with therapeutic delivery in normal use. The technology activates only when misuse is attempted. If chewed, smoked, or dissolved, the patch releases an aversive agent formula combining denatonium benzoate and Bitrex—the bitterest substances known—making misuse physically intolerable within seconds.

 

Addressing a Real and Growing Crisis

 

Traditional fentanyl patches often retain residual drug after use, creating deadly risks when discarded patches are found by children or misused by others. These dangers have fueled rising accidental deaths and deepened physician reluctance to prescribe fentanyl, even when clinically appropriate. AVERSA™ directly addresses this reality, allowing clinicians to prescribe effective pain relief with dramatically reduced concern about diversion, misuse, or accidental exposure.

 

Scaling a New Safety Standard

 

Nutriband has patents covering its AVERSA technology in 46 countries, providing 20-year protection for AVERSA™ technology. With FDA approval targeted within the next 12 to 18 months and commercial availability projected for 2027, the company plans to expand AVERSA™ into buprenorphine and morphine patches shortly thereafter. Beyond individual products, Serguei envisions AVERSA™ as a platform technology capable of becoming a regulatory benchmark—one that could influence future FDA guidance and reshape how safety is engineered into every narcotic patch prescribed worldwide.

 

This long-term vision reflects Nutribrand’s core values: advancing innovation that protects patients without compromising care. By preserving fentanyl’s unmatched efficacy while neutralizing its most dangerous risks, AVERSA™ represents a rare convergence of science, ethics, and accountability—one that could restore physician confidence, protect vulnerable populations, and redefine trust in pain management for generations to come.
 

 

Serguei Melnik
President, Co- Founder, Chairman
Nutribrand
Website: https://www.nutriband.com/

LinkedIn: https://www.linkedin.com/in/serguei-melnik-97b0446/